Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Tuberculosis

Free Subscription Articles published in Int J Tuberc Lung Dis Retrieve available abstracts of 281 articles: HTML format

Single Articles

December 2022
1. NOESKE J, Kuaban C
   Tailored TB preventive treatment for drug-resistant TB - failing the test for appropriateness?
   Int J Tuberc Lung Dis. 2022;26:1198.
   PubMed    
   
   
   
2. ALFFENAAR JWC, Marais BJ, Touw DJ
   Paediatric formulations for the treatment of drug resistant TB: closing the gaps.
   Int J Tuberc Lung Dis. 2022;26:1097-1100.
   PubMed    
   
   
   
3. IZUDI J, Sheira LA, Bajunirwe F, McCoy SI, et al
   Effect of 6-month vs. 8-month regimen on retreatment success for pulmonary TB.
   Int J Tuberc Lung Dis. 2022;26:1188-1190.
   PubMed    
   
   
   
4. DATTA A, Mohapatra PR, Bhuniya S, Mishra B, et al
   TB treatment regimen for children: is a 4-month regimen really better than the 6-month regimen?
   Int J Tuberc Lung Dis. 2022;26:1197.
   PubMed    
   
   
   
5. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
   Stable sugar and sugar-free suspensions of pretomanid.
   Int J Tuberc Lung Dis. 2022;26:1112-1117.
   PubMed     Abstract available
   
   
   
6. DEVOID I, Sillah AK, Sutherland J, Owolabi O, et al
   The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia.
   Int J Tuberc Lung Dis. 2022;26:1162-1169.
   PubMed     Abstract available
   
   
   
7. MEMANI B, Furin J, Cox H, Reuter A, et al
   A very sneaky bug: perspectives of front-line clinicians on whole-genome sequencing for drug-resistant TB.
   Int J Tuberc Lung Dis. 2022;26:1180-1182.
   PubMed    
   
   
   November 2022
8. GRANOZZI B, Bisognin F, Tadolini M, Lombardi G, et al
   IGRA test for TB in COVID-19: role of corticosteroids.
   Int J Tuberc Lung Dis. 2022;26:1088-1091.
   PubMed    
   
   
   
9. SMITH-JEFFCOAT SE, Eisenach KD, Joloba M, Ssengooba W, et al
   Quantification of multidrug-resistant M. tuberculosis bacilli in sputum during the first 8 weeks of treatment.
   Int J Tuberc Lung Dis. 2022;26:1058-1064.
   PubMed     Abstract available
   
   
   
10. GARCIA-GOEZ JF, Tello-Cajiao ME, Vargas-Potes CJ, Penagos-Luna R, et al
    Effect of biological therapies on TB treatment outcomes.
    Int J Tuberc Lung Dis. 2022;26:1077-1079.
    PubMed    
    
    
    
11. DIEFENBACH-ELSTOB T, Rivest P, Benedetti A, Gordon C, et al
    Patterns and characteristics of TB among key risk groups in Canada, 1993-2018.
    Int J Tuberc Lung Dis. 2022;26:1041-1049.
    PubMed     Abstract available
    
    
    
12. VELAYUTHAM B, Shah V, Mythily V, Gopalaswamy R, et al
    Factors influencing treatment outcomes in patients with isoniazid-resistant pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:1033-1040.
    PubMed     Abstract available
    
    
    
13. WILLEMSTEIN IJM, de Vries G, Essink DR, Slump E, et al
    TB in migrants residing in the Netherlands for at least 5 years at diagnosis, 2003-2018.
    Int J Tuberc Lung Dis. 2022;26:1050-1057.
    PubMed     Abstract available
    
    
    
14. KRISHNAN N, Siddiqi K, Dogar O, Gabe R, et al
    Predictors of long-term smoking abstinence in TB patients.
    Int J Tuberc Lung Dis. 2022;26:1074-1076.
    PubMed    
    
    
    
15. BARRETT R, Creswell J, Sahu S, Qin ZZ, et al
    User perspectives on the use of X-rays and computer-aided detection for TB.
    Int J Tuberc Lung Dis. 2022;26:1083-1085.
    PubMed    
    
    
    
16. TRAORE M, Nguhiu P, Telly N, Traore S, et al
    The high costs facing TB-affected households in Mali.
    Int J Tuberc Lung Dis. 2022;26:1071-1073.
    PubMed    
    
    
    October 2022
17. AIA P, Viney K, Kal M, Kisomb J, et al
    The economic burden of TB faced by patients and affected families in Papua New Guinea.
    Int J Tuberc Lung Dis. 2022;26:934-941.
    PubMed     Abstract available
    
    
    
18. MARAIS BJ, Bernays S, Schaaf HS, Fox GJ, et al
    Increasing TB preventive treatment in children.
    Int J Tuberc Lung Dis. 2022;26:903-905.
    PubMed    
    
    
    
19. TYEKU N, Apolisi I, Daniels J, Beko B, et al
    Pediatric delamanid treatment for children with rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:986-988.
    PubMed    
    
    
    
20. MENEZES D, Zenner D, Aldridge R, Anderson SR, et al
    Country differences and determinants of yield in programmatic migrant TB screening in four European countries.
    Int J Tuberc Lung Dis. 2022;26:942-948.
    PubMed     Abstract available
    
    
    
21. CATES L, Codreanu A, Ciobanu N, Fosburgh H, et al
    Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova.
    Int J Tuberc Lung Dis. 2022;26:963-969.
    PubMed     Abstract available
    
    
    
22. BLACKBOURN H, Tiberi S, Felker I
    Literature Highlights.
    Int J Tuberc Lung Dis. 2022;26:914-916.
    PubMed     Abstract available
    
    
    
23. PORRETTA AD, Manga S, Pontali E
    TB care in prisons: the ongoing challenge.
    Int J Tuberc Lung Dis. 2022;26:906-907.
    PubMed    
    
    
    
24. DIALLO A, Combary A, Bakyono R, Guene H, et al
    A 2020 baseline assessment for the monitoring of the End TB indicator of catastrophic costs in Burkina Faso.
    Int J Tuberc Lung Dis. 2022;26:970-977.
    PubMed     Abstract available
    
    
    
25. ROUZIER V, Murrill M, Kim S, Naini L, et al
    Caregiver willingness to give TPT to children living with drug-resistant TB patients.
    Int J Tuberc Lung Dis. 2022;26:949-955.
    PubMed     Abstract available
    
    
    
26. SCHWALB A, Emery JC, Houben RMGJ
    Use of chest radiography screening for TB: a re-evaluation of the Kolin study.
    Int J Tuberc Lung Dis. 2022;26:983-985.
    PubMed    
    
    
    
27. FATIMA R, Yaqoob A, Qadeer E, Khan MA, et al
    Community- vs. hospital-based management of multidrug-resistant TB in Pakistan.
    Int J Tuberc Lung Dis. 2022;26:929-933.
    PubMed     Abstract available
    
    
    
28. MANGOCHI P, Bossard C, Catacutan C, Van Laeken D, et al
    TB screening, prevention and treatment cascade in a Malawi prison.
    Int J Tuberc Lung Dis. 2022;26:956-962.
    PubMed     Abstract available
    
    
    September 2022
29. FARIA N, Reis R
    Screening for TB infection: the operator s impact.
    Int J Tuberc Lung Dis. 2022;26:857-861.
    PubMed     Abstract available
    
    
    
30. MOHAPATRA PR, Mishra B, Dutta A, Bhuniya S, et al
    Responding to WHO s 4-month regimen for drug-susceptible pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:898-899.
    PubMed    
    
    
    
31. KHAN U, Guglielmetti L
    Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:900-901.
    PubMed    
    
    
    
32. SABI I, Olomi W, Nkereuwem E, Togun T, et al
    Diagnosis of paediatric TB using Xpert((R)) MTB/RIF Ultra on fresh respiratory samples.
    Int J Tuberc Lung Dis. 2022;26:862-868.
    PubMed     Abstract available
    
    
    
33. SANTOS AP, Silva DR, Miranda G, Braga MS, et al
    Xpert((R)) MTB/RIF Ultra: detection of extrapulmonary TB in a high-burden setting.
    Int J Tuberc Lung Dis. 2022;26:880-882.
    PubMed    
    
    
    
34. DURET A, Olgemoeller F, Ferreras-Antolin L, Whittaker E, et al
    Paediatric TB care in the United Kingdom.
    Int J Tuberc Lung Dis. 2022;26:814-819.
    PubMed     Abstract available
    
    
    
35. SHUKLA A, Bromage S, Dholakia Y, Hemler EC, et al
    Case-control study of vitamin D status and adult multidrug-resistant pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:826-834.
    PubMed     Abstract available
    
    
    
36. CHO EJ, Kang MR, Kim JH, Lee JI, et al
    Evaluation of the MolecuTech((R)) REBA MTB-XMDR kit for detection of pre-extensively drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:869-874.
    PubMed     Abstract available
    
    
    
37. SCHWALB A, Cachay R, Wright A, Phillips PPJ, et al
    Factors associated with screening failure and study withdrawal in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:820-825.
    PubMed     Abstract available
    
    
    
38. TABERNERO E, Rodrigo T, Garros J, Altube L, et al
    TB in the elderly: clinical features and outcomes.
    Int J Tuberc Lung Dis. 2022;26:842-849.
    PubMed     Abstract available
    
    
    
39. KRAEF C, Yedilbayev A, Seguy N, Bentzon A, et al
    Uptake of the lateral flow urine LAM test in Europe and Central Asia.
    Int J Tuberc Lung Dis. 2022;26:835-841.
    PubMed     Abstract available
    
    
    August 2022
40. WEBER SF, Ruby LC, Heller T, Hande M, et al
    TB disease patterns by HIV and diabetes status.
    Int J Tuberc Lung Dis. 2022;26:733-740.
    PubMed     Abstract available
    
    
    
41. MALIK AA, Siddique M, Chandir S, Jaswal M, et al
    Travel reimbursements, distance to health facility and preventive treatment cascade for drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:789-791.
    PubMed    
    
    
    
42. MAGOHE A, Kimario J, Lukmanji Z, Hendricks K, et al
    Randomized, controlled trial of a protein-calorie supplement for women coinfected with HIV-TB.
    Int J Tuberc Lung Dis. 2022;26:798-800.
    PubMed    
    
    
    
43. JASWAL M, Farooq S, Madhani F, Noorani S, et al
    Implementing 3HP vs. IPT as TB preventive treatment in Pakistan.
    Int J Tuberc Lung Dis. 2022;26:741-746.
    PubMed     Abstract available
    
    
    
44. CASALME DJO, Marcelo DB, Dela Cuesta DM, Tonquin M, et al
    Feasibility and acceptability of asynchronous VOT among patients with MDR-TB.
    Int J Tuberc Lung Dis. 2022;26:760-765.
    PubMed     Abstract available
    
    
    
45. CHHABRA S, Ong CWM, Sotgiu G
    TB diagnosis and treatment during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2022;26:702-703.
    PubMed    
    
    
    
46. VERGEER SB, Oldenkamp R, Senkoro M, Mfinanga S, et al
    Does distance to healthcare facility affect care-seeking for TB-related symptoms in Tanzania?
    Int J Tuberc Lung Dis. 2022;26:747-752.
    PubMed     Abstract available
    
    
    
47. GEBRESELASSIE N, Falzon D, Zignol M, Viney K, et al
    Bridging the gap: key evidence needed to strengthen global policies to end TB.
    Int J Tuberc Lung Dis. 2022;26:704-707.
    PubMed    
    
    
    
48. NAQVI S, Cantu Y, Ong Uti S, Cavazos D, et al
    Successes and challenges of latent TB screening and treatment in a high-prevalence US region.
    Int J Tuberc Lung Dis. 2022;26:720-726.
    PubMed     Abstract available
    
    
    
49. KOKEBU DM, Ahmed S, Moodliar R, Chiang CY, et al
    Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.
    Int J Tuberc Lung Dis. 2022;26:753-759.
    PubMed     Abstract available
    
    
    
50. GIANNONI F, Lanni A, Iacobino A, Cirillo DM, et al
    Decreasing trend of drug-resistant TB in Italy.
    Int J Tuberc Lung Dis. 2022;26:775-783.
    PubMed     Abstract available
    
    
    
51. REKART ML, Morshed T, Mulanda WK, Klieascikova J, et al
    Family directly observed therapy for children with drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:792-794.
    PubMed    
    
    
    July 2022
52. ISMAIL F, Yousif A, Alfurjani M, Haq S, et al
    TB in eastern Libya: a decreasing trend in recent decades.
    Int J Tuberc Lung Dis. 2022;26:694-695.
    PubMed    
    
    
    
53. BASHAM CA, Orr PH
    Monitoring TB program performance.
    Int J Tuberc Lung Dis. 2022;26:692-693.
    PubMed    
    
    
    
54. NAIR P, Hasan T, Zaw KK, Allamuratova S, et al
    Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Int J Tuberc Lung Dis. 2022;26:658-663.
    PubMed     Abstract available
    
    
    
55. CARVALHO ACC, Kritski AL
    Community-based intervention and health education to scale up TB preventive treatment for children.
    Int J Tuberc Lung Dis. 2022;26:587-589.
    PubMed    
    
    
    
56. AKKERMAN OW, Duarte R, Tiberi S, Schaaf HS, et al
    Clinical standards for drug-susceptible pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:592-604.
    PubMed     Abstract available
    
    
    
57. VAN DER WERF TS, Grobusch MP
    Clinical standards for drug-susceptible TB: putting patients first.
    Int J Tuberc Lung Dis. 2022;26:584-586.
    PubMed    
    
    
    
58. NGUENHA D, Acacio S, Murias-Closas A, Ramanlal N, et al
    Prevalence and clinical characteristics of pulmonary TB among pregnant and post-partum women.
    Int J Tuberc Lung Dis. 2022;26:641-649.
    PubMed     Abstract available
    
    
    
59. VARSHNEY K, Rusnak JC
    TB reporting declines in priority countries during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2022;26:681-683.
    PubMed    
    
    
    
60. WEYENGA H, Onyango E, Katana AK, Pathmanathan I, et al
    Trends in TB and HIV care and treatment cascade, Kenya, 2008-2018.
    Int J Tuberc Lung Dis. 2022;26:623-628.
    PubMed     Abstract available
    
    
    
61. MIGLIORI GB, Tiberi S
    WHO drug-resistant TB guidelines 2022: what is new?
    Int J Tuberc Lung Dis. 2022;26:590-591.
    PubMed    
    
    
    
62. KAMBILI C, Rossenu S, Hoetelmans RMW, Birmingham E, et al
    Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:671-677.
    PubMed     Abstract available
    
    
    June 2022
63. LAZARCHIK A, Nyaruhirira AU, Chiang CY, Wares F, et al
    Global availability of susceptibility testing for second-line anti-tuberculosis agents.
    Int J Tuberc Lung Dis. 2022;26:524-528.
    PubMed     Abstract available
    
    
    
64. PELZER PT, Smit Y, Tiemersma EW, Huong NT, et al
    Does BCG vaccination protect against infection with M. tuberculosis?
    Int J Tuberc Lung Dis. 2022;26:529-536.
    PubMed     Abstract available
    
    
    
65. SINHA P, Bhargava A, Carwile M, Cintron C, et al
    Undernutrition can no longer be an afterthought for global efforts to eliminate TB.
    Int J Tuberc Lung Dis. 2022;26:477-480.
    PubMed    
    
    
    
66. BOEKELHEIDE K, Olugbosi M, Nedelman J, Everitt D, et al
    Male reproductive hormones in patients treated with pretomanid.
    Int J Tuberc Lung Dis. 2022;26:558-565.
    PubMed     Abstract available
    
    
    
67. KANIGA K, Lounis N, Zhuo S, Bakare N, et al
    Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline.
    Int J Tuberc Lung Dis. 2022;26:571-573.
    PubMed    
    
    
    
68. LAURSEN LL, Dahl VN, Wejse C
    Stool testing for pulmonary TB diagnosis in adults.
    Int J Tuberc Lung Dis. 2022;26:516-523.
    PubMed     Abstract available
    
    
    
69. SHIN AY, Jekarl DW, Kim HW, Ha JH, et al
    Early line-probe assay using DNA specimens in patients with pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:509-515.
    PubMed     Abstract available
    
    
    
70. NAUFAL F, Chaisson LH, Robsky KO, Delgado-Barroso P, et al
    Number needed to screen for TB in clinical, structural or occupational risk groups.
    Int J Tuberc Lung Dis. 2022;26:500-508.
    PubMed     Abstract available
    
    
    
71. MALIK AA, Amanullah F
    Source case investigation can reduce the diagnostic gap for childhood TB.
    Int J Tuberc Lung Dis. 2022;26:566-567.
    PubMed    
    
    
    May 2022
72. GRANOZZI B, Bisognin F, Lombardi G, Dal Monte P, et al
    TB mortality in low-incidence countries: can we reduce it further?
    Int J Tuberc Lung Dis. 2022;26:467-469.
    PubMed    
    
    
    
73. GROSCHEL MI, van den Boom M, Dixit A, Skrahina A, et al
    Management of childhood MDR-TB in Europe and Central Asia: report of a Regional WHO meeting.
    Int J Tuberc Lung Dis. 2022;26:433-440.
    PubMed     Abstract available
    
    
    
74. SHAMPUTA IC, Nguyen DTK, Burdo T, Dao G, et al
    Canadian immigrants awareness and perceptions of TB infection and TB.
    Int J Tuberc Lung Dis. 2022;26:454-456.
    PubMed    
    
    
    
75. COOREY NJ, Kensitt L, Davies J, Keller E, et al
    Risk factors for TB in Australia and their association with delayed treatment completion.
    Int J Tuberc Lung Dis. 2022;26:399-405.
    PubMed     Abstract available
    
    
    
76. KRITSKI AL, Viveiros M, Carvalho ACC
    Rapid molecular diagnostics to detect resistance to second-line anti-TB drugs.
    Int J Tuberc Lung Dis. 2022;26:385-387.
    PubMed    
    
    
    
77. GANDHI R, Deepak KG, Verma G, Chaubey S, et al
    Engaging private pharmacies to help end TB in India.
    Int J Tuberc Lung Dis. 2022;26:457-459.
    PubMed    
    
    
    
78. NINAN MM, Rupali P, Varghese GM, Shalini EB, et al
    Xpert Ultra in diagnosing extrapulmonary TB: accuracy and trace calls.
    Int J Tuberc Lung Dis. 2022;26:441-445.
    PubMed     Abstract available
    
    
    
79. MALIK AA, Hussain H
    Preventive treatment for MDR-TB exposure in households.
    Int J Tuberc Lung Dis. 2022;26:466-467.
    PubMed    
    
    
    
80. CAPEDING TPJ, Rosa JD, Lam H, Gaviola DG, et al
    Cost of TB prevention and treatment in the Philippines in 2017.
    Int J Tuberc Lung Dis. 2022;26:392-398.
    PubMed     Abstract available
    
    
    
81. PALANI N, Premkumar M, Vaishnavee V, Dinesh V, et al
    Trends in rifampicin and isoniazid resistance in patients with presumptive TB.
    Int J Tuberc Lung Dis. 2022;26:446-453.
    PubMed     Abstract available
    
    
    April 2022
82. MARCHESE V, Formenti B, Marchese L, Gregori N, et al
    COVID-19 effect on TB presentation and outcome.
    Int J Tuberc Lung Dis. 2022;26:375-377.
    PubMed    
    
    
    
83. KIM JW, Vella C, Parvez W, Verma R, et al
    Impact of COVID-19 on the diagnosis and management of lung cancer and TB.
    Int J Tuberc Lung Dis. 2022;26:372-374.
    PubMed    
    
    
    
84. ALLORANT A, Biswas S, Ahmed S, Wiens KE, et al
    Finding gaps in routine TB surveillance activities in Bangladesh.
    Int J Tuberc Lung Dis. 2022;26:356-362.
    PubMed     Abstract available
    
    
    
85. SHIVAKUMAR SVBY, Padmapriyadarsini C, Chavan A, Paradkar M, et al
    Concomitant pulmonary disease is common among patients with extrapulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:341-347.
    PubMed     Abstract available
    
    
    
86. HUGHES G, Bern H, Chiang CY, Goodall RL, et al
    QT prolongation in the STREAM Stage 1 Trial.
    Int J Tuberc Lung Dis. 2022;26:334-340.
    PubMed     Abstract available
    
    
    
87. DEN BOON S, Lienhardt C, Zignol M, Schwartzman K, et al
    WHO target product profiles for TB preventive treatment.
    Int J Tuberc Lung Dis. 2022;26:302-309.
    PubMed     Abstract available
    
    
    
88. ADAMASHVILI N, Baliashvili D, Kuchukhidze G, Salindri AD, et al
    Low BMI increases all-cause mortality rates in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:326-333.
    PubMed     Abstract available
    
    
    
89. PRADHAN NN, Paradkar MS, Kagal A, Valvi C, et al
    Performance of Xpert((R)) MTB/RIF and Xpert((R)) Ultra for the diagnosis of tuberculous meningitis in children.
    Int J Tuberc Lung Dis. 2022;26:317-325.
    PubMed     Abstract available
    
    
    
90. DOWDY DW, Islam MA
    Finding TB s "missing millions", one district at a time.
    Int J Tuberc Lung Dis. 2022;26:295.
    PubMed    
    
    
    March 2022
91. SUMNER T, Jensen HT, Keogh-Brown MR, Vassall A, et al
    Time to integrate epidemiological and economic models for TB.
    Int J Tuberc Lung Dis. 2022;26:282-284.
    PubMed    
    
    
    
92. MBELELE PM, Sabiiti W, Heysell SK, Sauli E, et al
    Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease.
    Int J Tuberc Lung Dis. 2022;26:276-278.
    PubMed    
    
    
    
93. MUSONDA HK, Rose PC, Switala J, Schaaf HS, et al
    Paediatric admissions to a TB hospital: reasons for admission, clinical profile and outcomes.
    Int J Tuberc Lung Dis. 2022;26:217-223.
    PubMed     Abstract available
    
    
    
94. MIGLIORI GB, Wu SJ, Matteelli A, Zenner D, et al
    Clinical standards for the diagnosis, treatment and prevention of TB infection.
    Int J Tuberc Lung Dis. 2022;26:190-205.
    PubMed     Abstract available
    
    
    February 2022
95. TINOCO EM, Vasconcelos A, Alves F, Duarte R, et al
    Impact of COVID-19 on extrapulmonary TB and the benefit of decentralised TB services.
    Int J Tuberc Lung Dis. 2022;26:178-180.
    PubMed    
    
    
    
96. ORTIZ-MARTINEZ Y, Rodriguez-Morales AJ, Henao-Martinez AF
    Decreased notification of TB cases during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2022;26:177-178.
    PubMed    
    
    
    
97. SCHIZA V, Kruse M, Xiao Y, Kar S, et al
    Impact of the COVID-19 pandemic on TB infection testing.
    Int J Tuberc Lung Dis. 2022;26:174-176.
    PubMed    
    
    
    
98. GUREVA T, Turkova A, Yablokova E, Smirnova P, et al
    Fluoroquinolone preventive therapy for children exposed to MDR-TB.
    Int J Tuberc Lung Dis. 2022;26:171-173.
    PubMed    
    
    
    
99. BOHLBRO AS, Patsche CB, Mendes AM, Sifna A, et al
    A self-rated health score predicts severe disease and high mortality in patients with pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:158-165.
    PubMed     Abstract available
    
    
    
100. MOHR-HOLLAND E, Daniels J, Reuter A, Rodriguez CA, et al
     Early mortality during rifampicin-resistant TB treatment.
     Int J Tuberc Lung Dis. 2022;26:150-157.
     PubMed     Abstract available
     
     
     
101. BEAUMONT AL, Doumbia A, Chateau N, Meynard JL, et al
     Why are people still dying of drug-susceptible TB in Paris in the 21(st) century?
     Int J Tuberc Lung Dis. 2022;26:142-149.
     PubMed     Abstract available
     
     
     
102. LOPEZ-VARELA E, Garcia-Prats AJ, Seddon JA, Draper HR, et al
     Treatment outcomes and safety in children with rifampicin-resistant TB.
     Int J Tuberc Lung Dis. 2022;26:133-141.
     PubMed     Abstract available
     
     
     
103. BURHAN E, Soepandi PZ, Isbaniah F, Damayanti K, et al
     Determinants of treatment outcomes in patients with multidrug-resistant TB.
     Int J Tuberc Lung Dis. 2022;26:126-132.
     PubMed     Abstract available
     
     
     
104. HOSSAIN MD, Rahim MA, Islam N, Afroze F, et al
     TB prevalence among patients with diabetes in Bangladesh.
     Int J Tuberc Lung Dis. 2022;26:119-125.
     PubMed     Abstract available
     
     
     
105. KHAWCHAROENPORN T, Noisang K
     Incomplete contact investigation and risk of developing TB among healthcare professionals.
     Int J Tuberc Lung Dis. 2022;26:111-118.
     PubMed     Abstract available
     
     
     
106. APRIANI L, Koesoemadinata RC, Bastos ML, Wulandari DA, et al
     Implementing the 4R and 9H regimens for TB preventive treatment in Indonesia.
     Int J Tuberc Lung Dis. 2022;26:103-110.
     PubMed     Abstract available
     
     
     
107. ILAIWY G, Heysell SK, Thomas TA
     National approaches to TB care in adolescents.
     Int J Tuberc Lung Dis. 2022;26:96-102.
     PubMed     Abstract available
     
     
     
108. SILVA DR, de Queiroz Mello FC
     Improving outcomes for multidrug-resistant TB treatment.
     Int J Tuberc Lung Dis. 2022;26:93-95.
     PubMed    
     
     
     
109. BARRETT J
     Why are people still dying from TB in low-burden countries?
     Int J Tuberc Lung Dis. 2022;26:91-92.
     PubMed    
     
     
     
110. HARRIES AD, Zellweger JP
     Protecting healthcare workers from TB.
     Int J Tuberc Lung Dis. 2022;26:89-90.
     PubMed    
     
     
     
111. GRAHAM SM, Amanullah F
     Updated guidelines for child and adolescent TB.
     Int J Tuberc Lung Dis. 2022;26:81-84.
     PubMed    
     
     
     
112. LANGE C, Kay A, Mandalakas AM
     The need for effective drugs for TB prevention: set your goals high, and don t stop till you get there.
     Int J Tuberc Lung Dis. 2022;26:85-88.
     PubMed    
     
     
     January 2022
113. TADOLINI M, Onozaki I
     National TB prevalence surveys in the COVID-19 era.
     Int J Tuberc Lung Dis. 2022;26:4-5.
     PubMed    
     
     
     
114. SINHA P, White LF, Hochberg NS, Cegielski JP, et al
     Avoiding pitfalls in calculating the population attributable fraction of undernutrition for TB.
     Int J Tuberc Lung Dis. 2022;26:80.
     PubMed    
     
     
     
115. KLAOS K, Holicka Y, Groenheit R, Kodmon C, et al
     Current state of national TB laboratory networks in Europe: achievements and challenges.
     Int J Tuberc Lung Dis. 2022;26:71-73.
     PubMed    
     
     
     
116. OJUAWO O, Piracha S, Irshad S, Mirza M, et al
     Tuberculous mastitis in a low-incidence setting: should respiratory physicians be concerned?
     Int J Tuberc Lung Dis. 2022;26:69-70.
     PubMed    
     
     
     
117. PETRUCCIOLI E, Farroni C, Cuzzi G, Vanini V, et al
     VIDAS((R)) TB-IGRA reagents induce a CD4(+) and CD8(+) T-cell IFN-gamma response for both TB infection and active TB.
     Int J Tuberc Lung Dis. 2022;26:65-68.
     PubMed    
     
     
     
118. CHIPINDURO M, Timire C, Chirenda J, Matambo R, et al
     TB prevalence in Zimbabwe: a national cross-sectional survey, 2014.
     Int J Tuberc Lung Dis. 2022;26:57-64.
     PubMed     Abstract available
     
     
     
119. ACOSTA J, Flores P, Alarcon M, Grande-Ortiz M, et al
     A randomised controlled trial to evaluate a medication monitoring system for TB treatment.
     Int J Tuberc Lung Dis. 2022;26:44-49.
     PubMed     Abstract available
     
     
     December 2021
120. ZAMANI S, Honarvar MR, Behnampour N, Sheikhy M, et al
     Decline in TB incidence during the COVID-19 pandemic.
     Int J Tuberc Lung Dis. 2021;25:1043-1044.
     PubMed    
     
     
     
121. SUMNER T, Fiore-Gartland A, Hatherill M, Houben RMGJ, et al
     The effect of new Mycobacterium tuberculosis infection on the sensitivity of prognostic TB signatures.
     Int J Tuberc Lung Dis. 2021;25:1001-1005.
     PubMed     Abstract available
     
     
     
122. SARDA R, Ray A
     Pulmonary TB and chronic pulmonary aspergillosis.
     Int J Tuberc Lung Dis. 2021;25:1042-1043.
     PubMed    
     
     
     
123. TESFAHUN H, Moussally K, Al-Ani NA, Al-Salhi LG, et al
     Introduction of new drugs for drug-resistant TB in Iraq.
     Int J Tuberc Lung Dis. 2021;25:1041-1042.
     PubMed    
     
     
     
124. CHATTERJEE S, Toshniwal MN, Bhide P, Sachdeva KS, et al
     Costs of TB services in India (No 1).
     Int J Tuberc Lung Dis. 2021;25:1013-1018.
     PubMed     Abstract available
     
     
     
125. ZHU H, Xie L, Liu ZQ, Wang B, et al
     Population pharmacokinetics of bedaquiline in patients with drug-resistant TB.
     Int J Tuberc Lung Dis. 2021;25:1006-1012.
     PubMed     Abstract available
     
     
     
126. NIKOLENKA A, Mansjo M, Skrahina A, Hurevich H, et al
     Whole-genome sequencing differentiates relapse from re-infection in TB.
     Int J Tuberc Lung Dis. 2021;25:995-1000.
     PubMed     Abstract available
     
     
     
127. LEE JJ, Kang HY, Lee WI, Cho SY, et al
     Efflux pump gene expression study using RNA-seq in multidrug-resistant TB.
     Int J Tuberc Lung Dis. 2021;25:974-981.
     PubMed     Abstract available
     
     
     
128. TELISINGHE L, Shaweno D, Hayes RJ, Dodd PJ, et al
     The effect of systematic screening of the general population on TB case notification rates.
     Int J Tuberc Lung Dis. 2021;25:964-973.
     PubMed     Abstract available
     
     
     November 2021
129. ANTONY S, Bodhanwala M, Shah I
     Clinical profile and outcomes of paediatric central nervous system tuberculomas.
     Int J Tuberc Lung Dis. 2021;25:953-955.
     PubMed    
     
     
     
130. FUKUSHIMA K, Akagi K, Kondoh A, Kubo T, et al
     Evaluation of QFT-Plus performance using blood samples stored at room temperature.
     Int J Tuberc Lung Dis. 2021;25:948-949.
     PubMed    
     
     
     
131. WOLTERS BA, Aartsma Y, Jansen K, van Hest R, et al
     Travel history and challenges of screening for latent TB infection in child asylum seekers.
     Int J Tuberc Lung Dis. 2021;25:945-947.
     PubMed    
     
     
     
132. CHRISTOPHER DJ, Coelho V, Ebby GS, Shankar D, et al
     Incremental yield of Xpert((R)) MTB/RIF Ultra over Xpert((R)) MTB/RIF in the diagnosis of extrapulmonary TB.
     Int J Tuberc Lung Dis. 2021;25:939-944.
     PubMed     Abstract available
     
     
     
133. GATECHOMPOL S, Sophonphan J, Kerr SJ, Ubolyam S, et al
     Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV.
     Int J Tuberc Lung Dis. 2021;25:933-938.
     PubMed     Abstract available
     
     
     
134. KASWA M, Minga G, Nkiere N, Mingiedi B, et al
     The economic burden of TB-affected households in DR Congo.
     Int J Tuberc Lung Dis. 2021;25:923-932.
     PubMed     Abstract available
     
     
     
135. STIEBER F, Howard J, Manissero D, Boyle J, et al
     Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis.
     Int J Tuberc Lung Dis. 2021;25:917-922.
     PubMed     Abstract available
     
     
     
136. MURITHI W, Click ES, McCarthy KD, Okeyo E, et al
     Need for caution when interpreting Xpert((R)) MTB/RIF results for rifampin resistance among children.
     Int J Tuberc Lung Dis. 2021;25:911-916.
     PubMed     Abstract available
     
     
     
137. LUAN L, Fraisse P, Cordel H, Charlois C, et al
     Screening for active and latent TB among migrants in France.
     Int J Tuberc Lung Dis. 2021;25:903-910.
     PubMed     Abstract available
     
     
     
138. WINCKLER JL, Schaaf HS, Draper HR, McIlleron H, et al
     Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB.
     Int J Tuberc Lung Dis. 2021;25:896-902.
     PubMed     Abstract available
     
     
     
139. TAAFFE J, Croda J, Moultrie H, Silva DS, et al
     Advancing TB research using digitized programmatic data.
     Int J Tuberc Lung Dis. 2021;25:890-895.
     PubMed     Abstract available
     
     
     
140. BOEREE MJ, Lange C, Thwaites G, Paton N, et al
     UNITE4TB: a new consortium for clinical drug and regimen development for TB.
     Int J Tuberc Lung Dis. 2021;25:886-889.
     PubMed    
     
     
     
141. OCHERETINA O, Brandao AP, Pang Y, Rodrigues C, et al
     Impact of the bacillary load on the accuracy of rifampicin resistance results by Xpert((R)) MTB/RIF.
     Int J Tuberc Lung Dis. 2021;25:881-885.
     PubMed    
     
     
     
142. ALFFENAAR JC, Marais BJ, Thomas TA
     Is a high dose sufficient to achieve high isoniazid exposure in children affected by multidrug-resistant TB?
     Int J Tuberc Lung Dis. 2021;25:879-880.
     PubMed    
     
     
     October 2021
143. SEKANDI JN, Tucker EG, Zalwango S, Buregyeya E, et al
     Digital technologies and loss to follow-up for TB patients.
     Int J Tuberc Lung Dis. 2021;25:871-872.
     PubMed    
     
     
     
144. HASSAN L, Ali SM, Iqbal W, Baig S, et al
     Automated detection and reduction of stigma in online discussions about TB.
     Int J Tuberc Lung Dis. 2021;25:869-870.
     PubMed    
     
     
     
145. ARENAS-MIRAS M, Sanchez-Martinez F, Jove-Caballe N, Villar-Garcia J, et al
     Clinical experience of TB in patients treated with anti-TNF-alpha.
     Int J Tuberc Lung Dis. 2021;25:866-868.
     PubMed    
     
     
     
146. TAHSEEN S, Khanzada FM, Hussain A, Akhtar N, et al
     Phenotypic vs. genotypic resistance to fluoroquinolones in rifampicin-resistant TB.
     Int J Tuberc Lung Dis. 2021;25:861-863.
     PubMed    
     
     
     
147. EJO M, Van Deun A, Nunn A, Meredith S, et al
     Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial.
     Int J Tuberc Lung Dis. 2021;25:839-845.
     PubMed     Abstract available
     
     
     
148. BLACK M, Da Silva P, Scott L
     Rifampicin-resistant TB: discordance between Xpert((R)) MTB/RIF and MTBDRplus results.
     Int J Tuberc Lung Dis. 2021;25:832-838.
     PubMed     Abstract available
     
     
     
149. OXLADE O, den Boon S, Menzies D, Falzon D, et al
     TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up.
     Int J Tuberc Lung Dis. 2021;25:823-831.
     PubMed     Abstract available
     
     
     
150. PURCHASE S, Batist E, Mmile N, Nkosi S, et al
     Challenges in recruiting children to a multidrug-resistant TB prevention trial.
     Int J Tuberc Lung Dis. 2021;25:814-822.
     PubMed     Abstract available
     
     
     September 2021
151. KOZINSKA M, Podlasin R, Ropelewska-Lacka K, Wojtycha-Kwasnica B, et al
     TB and COVID-19 coinfection.
     Int J Tuberc Lung Dis. 2021;25:776-777.
     PubMed    
     
     
     
152. MOHR-HOLLAND E, Hacking D, Daniels J, Scott V, et al
     Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19.
     Int J Tuberc Lung Dis. 2021;25:772-775.
     PubMed    
     
     
     
153. GIGANTE AR, Sousa M, Aguiar A, Pinto M, et al
     The impact of COVID-19 on the TB response: data from the field.
     Int J Tuberc Lung Dis. 2021;25:769-771.
     PubMed    
     
     
     
154. SHIN JE, Jo KW, O YJ, Jeon D, et al
     Impact of revised definitions for extensively drug-resistant TB on disease classification.
     Int J Tuberc Lung Dis. 2021;25:766-768.
     PubMed    
     
     
     
155. GUTIERREZ A, Isidro A, Herrerin J, Hinojosa J, et al
     Meningeal TB in a mummified child from 4,000 years ago.
     Int J Tuberc Lung Dis. 2021;25:761-762.
     PubMed    
     
     
     
156. KAMOLWAT P, Nonghanphithak D, Chaiprasert A, Smithtikarn S, et al
     Diagnostic performance of whole-genome sequencing for identifying drug-resistant TB in Thailand.
     Int J Tuberc Lung Dis. 2021;25:754-760.
     PubMed     Abstract available
     
     
     
157. HUDDART S, Ingawale P, Edwin J, Jondhale V, et al
     TB case fatality and recurrence in a private sector cohort in Mumbai, India.
     Int J Tuberc Lung Dis. 2021;25:738-746.
     PubMed     Abstract available
     
     
     
158. MOODLIAR R, Aksenova V, Frias MVG, van de Logt J, et al
     Bedaquiline for multidrug-resistant TB in paediatric patients.
     Int J Tuberc Lung Dis. 2021;25:716-724.
     PubMed     Abstract available
     
     
     
159. MURPHY RA, Douglas-Jones B, Mucinya G, Sunpath H, et al
     Expanding the use of dolutegravir-based antiretroviral therapy in multidrug-resistant TB.
     Int J Tuberc Lung Dis. 2021;25:696-700.
     PubMed     Abstract available
     
     
     
160. CHESOV D, Makhanda G, Furin J
     Tackling the many layers of stigma is essential for the "End TB Strategy".
     Int J Tuberc Lung Dis. 2021;25:683-684.
     PubMed    
     
     
     August 2021
161. RANAIVOMANANA P, Knoblauch AM, Razafimahatratra MC, Raherinandrasana AH, et al
     Pulmonary and pleural TB prevalence in pregnant women.
     Int J Tuberc Lung Dis. 2021;25:668-670.
     PubMed    
     
     
     
162. EDDY JJ, Seth B, White LF, Sulis CA, et al
     Decreasing time spent in airborne infection isolation during TB testing.
     Int J Tuberc Lung Dis. 2021;25:665-667.
     PubMed    
     
     
     
163. CLARKSON MC, McQuaid CF, Houben RM, Kranzer K, et al
     Better data for country-level TB resource allocation are urgently required.
     Int J Tuberc Lung Dis. 2021;25:662-664.
     PubMed    
     
     
     
164. PERRY A, Chitnis A, Chin A, Hoffmann C, et al
     Real-world implementation of video-observed therapy in an urban TB program in the United States.
     Int J Tuberc Lung Dis. 2021;25:655-661.
     PubMed     Abstract available
     
     
     
165. SMITH AGC, Gujabidze M, Avaliani T, Blumberg HM, et al
     Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens.
     Int J Tuberc Lung Dis. 2021;25:632-639.
     PubMed     Abstract available
     
     
     
166. SHARMA K, Sharma M, Modi M, Singla N, et al
     Comparative analysis of Truenat MTB Plus and Xpert((R)) Ultra in diagnosing tuberculous meningitis.
     Int J Tuberc Lung Dis. 2021;25:626-631.
     PubMed     Abstract available
     
     
     
167. CAMPBELL JR, Katamba A, Oxlade O, Schwartzman K, et al
     Improving country-level modelling to support TB prevention and care.
     Int J Tuberc Lung Dis. 2021;25:607-608.
     PubMed    
     
     
     
168. DONOVAN J, Walker TM
     Diagnosing tuberculous meningitis: a testing process.
     Int J Tuberc Lung Dis. 2021;25:605-606.
     PubMed    
     
     
     July 2021
169. AMOUR M, von Reyn CF
     A new paradigm: testing household contacts of adolescents with incident TB infection.
     Int J Tuberc Lung Dis. 2021;25:599b-600.
     PubMed    
     
     
     
170. RODRIGUEZ CA, Brooks MB, Aibana O, Mitnick CD, et al
     Sputum culture conversion definitions and analytic practices for multidrug-resistant TB.
     Int J Tuberc Lung Dis. 2021;25:596-598.
     PubMed    
     
     
     
171. ERISA KC, Robsky KO, Kitonsa PJ, Nalutaaya A, et al
     Low prevalence of diabetes mellitus in TB patients and the community in urban Uganda.
     Int J Tuberc Lung Dis. 2021;25:590-592.
     PubMed    
     
     
     
172. DOUGLAS-JONES B, Mohr-Holland E, Mema N, Mathee S, et al
     A home-based care programme for rifampicin-resistant TB.
     Int J Tuberc Lung Dis. 2021;25:587-589.
     PubMed    
     
     
     
173. HABIB SS, Malik AA, Khan U, Khowaja S, et al
     Impact of upfront Xpert testing on time to treatment initiation for multidrug-resistant TB.
     Int J Tuberc Lung Dis. 2021;25:584-586.
     PubMed    
     
     
     
174. MORAN A, Lebona L, Makgopa G, Nkwane Y, et al
     One size does not fit all: reaching agricultural workers in South Africa with TB services.
     Int J Tuberc Lung Dis. 2021;25:573-578.
     PubMed     Abstract available
     
     
     
175. YANGTHARA B, Wutthigate P, Roongmaitree S, Siripattanapipong P, et al
     Nosocomial TB in two neonatal intensive care units at a tertiary care centre: infection risk and outcomes.
     Int J Tuberc Lung Dis. 2021;25:567-572.
     PubMed     Abstract available
     
     
     
176. BLACK DA, McBrien SW, Gersh J, Ghassemieh B, et al
     TB risk by time since U.S. entry among non-U.S.-born residents of Washington State, USA.
     Int J Tuberc Lung Dis. 2021;25:560-566.
     PubMed     Abstract available
     
     
     
177. FEUTH T, Patovirta RL, Grierson S, Danilovits M, et al
     Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines.
     Int J Tuberc Lung Dis. 2021;25:554-559.
     PubMed     Abstract available
     
     
     
178. LARGEN A, Ayala A, Khurana R, Katz DJ, et al
     Evaluation of point-of-care algorithms to detect diabetes during screening for latent TB infection.
     Int J Tuberc Lung Dis. 2021;25:547-553.
     PubMed     Abstract available
     
     
     
179. BALUKU JB, Nuwagira E, Bongomin F, Denning DW, et al
     Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities.
     Int J Tuberc Lung Dis. 2021;25:537-546.
     PubMed     Abstract available
     
     
     
180. SHARMA M, Onozaki I, Nunn P
     TB in older people in Asia: why it is important.
     Int J Tuberc Lung Dis. 2021;25:521-524.
     PubMed    
     
     
     
181. SALZER HJF, Wang JY
     Chronic pulmonary aspergillosis as a sequel to pulmonary TB.
     Int J Tuberc Lung Dis. 2021;25:519-520.
     PubMed    
     
     
     June 2021
182. AGOSTINIS A, Heffernan C, Long R, Beckon A, et al
     Interferon-gamma release assays for latent tuberculosis infection screening in Canadian federal correctional facilities.
     Int J Tuberc Lung Dis. 2021;25:447-452.
     PubMed     Abstract available
     
     
     
183. TEO AKJ, Ong CWM, Hsu LY
     COVID-19 and TB: a progression-regression conundrum.
     Int J Tuberc Lung Dis. 2021;25:421-423.
     PubMed    
     
     
     
184. BASHAM CA, Romanowski K, Johnston JC
     Alcohol use disorder and TB survivor health.
     Int J Tuberc Lung Dis. 2021;25:516-517.
     PubMed    
     
     
     
185. MANTSHONYANE L, Kgwaadira B, Gross R
     The absence of evidence of cure is not a risk for recurrent TB among patients treated for TB.
     Int J Tuberc Lung Dis. 2021;25:511-512.
     PubMed    
     
     
     
186. ROYCROFT E, Fitzgibbon MM, Kelly DM, Scully M, et al
     The largest prison outbreak of TB in Western Europe investigated using whole-genome sequencing.
     Int J Tuberc Lung Dis. 2021;25:491-497.
     PubMed     Abstract available
     
     
     
187. SZKWARKO D, Amisi JA, Peterson D, Burudi S, et al
     Using a mobile application to improve pediatric presumptive TB identification in western Kenya.
     Int J Tuberc Lung Dis. 2021;25:468-474.
     PubMed     Abstract available
     
     
     
188. REDWOOD L, Mitchell EMH, Viney K, Snow K, et al
     Depression, stigma and quality of life in people with drug-susceptible TB and drug-resistant TB in Vietnam.
     Int J Tuberc Lung Dis. 2021;25:461-467.
     PubMed     Abstract available
     
     
     
189. OELOFSE S, Esmail A, Diacon AH, Conradie F, et al
     Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
     Int J Tuberc Lung Dis. 2021;25:453-460.
     PubMed     Abstract available
     
     
     
190. CHAISSON LH, Naufal F, Delgado-Barroso P, Alvarez-Manzo HS, et al
     A systematic review of the number needed to screen for active TB among people living with HIV.
     Int J Tuberc Lung Dis. 2021;25:427-435.
     PubMed     Abstract available
     
     
     
191. TAVOSCHI L, Toscanini F, Pontali E
     TB and prisons: confinement does not contain the disease.
     Int J Tuberc Lung Dis. 2021;25:424-426.
     PubMed    
     
     
     
192. AKKERMAN OW, Tiberi S, Alffenaar JW
     Shortening MDR-TB treatment: is treating more patients with fewer drugs better?
     Int J Tuberc Lung Dis. 2021;25:419-420.
     PubMed    
     
     
     May 2021
193. ZOKUFA N, Lebelo K, Hacking D, Tabo L, et al
     Community-based TB testing as an essential part of TB recovery plans in the COVID-19 era.
     Int J Tuberc Lung Dis. 2021;25:406-408.
     PubMed    
     
     
     
194. POLLOCK NR, MacIntyre AT, Blauwkamp TA, Blair L, et al
     Detection of Mycobacterium tuberculosis cell-free DNA to diagnose TB in pediatric and adult patients.
     Int J Tuberc Lung Dis. 2021;25:403-405.
     PubMed    
     
     
     
195. MIN J, Kang JY, Kim J, Yang J, et al
     Impact of COVID-19 on TB services in Korea.
     Int J Tuberc Lung Dis. 2021;25:400-402.
     PubMed    
     
     
     
196. MARGINEANU I, Mor Z, Garcia D, Gilpin C, et al
     TB and COVID-19 in migrants - the need to focus on both conditions.
     Int J Tuberc Lung Dis. 2021;25:333-335.
     PubMed    
     
     
     
197. MCQUAID CF, Foster N, Quaife M, Levy J, et al
     Digital adherence technology for TB: focus on livelihoods as well as lives.
     Int J Tuberc Lung Dis. 2021;25:416-417.
     PubMed    
     
     
     
198. RICCARDI N, Saderi L, Borroni E, Tagliani E, et al
     Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.
     Int J Tuberc Lung Dis. 2021;25:395-399.
     PubMed     Abstract available
     
     
     
199. KALEMA N, Semeere A, Banturaki G, Kyamugabwa A, et al
     Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: an explanatory sequential cascade analysis.
     Int J Tuberc Lung Dis. 2021;25:388-394.
     PubMed     Abstract available
     
     
     
200. SATYANARAYANA S, Bhatia V, Mandal PP, Kanchar A, et al
     Urgent need to address the slow scale-up of TB preventive treatment in the WHO South-East Asia Region.
     Int J Tuberc Lung Dis. 2021;25:382-387.
     PubMed     Abstract available
     
     
     
201. FERREIRO L, Ruano-Ravina A, Otero-Mallo R, Pou-Alvarez C, et al
     Recent epidemiological trends in extrapulmonary TB in Galicia, Spain.
     Int J Tuberc Lung Dis. 2021;25:373-381.
     PubMed     Abstract available
     
     
     
202. WEYENGA H, Karanja M, Onyango E, Katana AK, et al
     Can isoniazid preventive therapy be scaled up rapidly? Lessons learned in Kenya, 2014-2018.
     Int J Tuberc Lung Dis. 2021;25:367-372.
     PubMed     Abstract available
     
     
     
203. MARTSON AG, Kim HY, Marais B, Alffenaar JW, et al
     The importance of pharmacokinetics/pharmacodynamics assessment in Phase IIB/III trials for MDR-TB treatment.
     Int J Tuberc Lung Dis. 2021;25:336-339.
     PubMed    
     
     
     April 2021
204. MALABAD JCM, Ang CF, Palabrica FAR, Cajucom MAM, et al
     Molecular epidemiology of Mycobacterium tuberculosis in adult Filipino TB-HIV co-infected patients.
     Int J Tuberc Lung Dis. 2021;25:285-291.
     PubMed     Abstract available
     
     
     
205. HARRIES AD, Kumar AMV, Satyanarayana S, Thekkur P, et al
     TB and COVID-19: measuring key risk factors that affect treatment outcomes.
     Int J Tuberc Lung Dis. 2021;25:329-331.
     PubMed    
     
     
     
206. COX V, Guglielmetti L, Hewison C, Reuter A, et al
     Reply to: "Human rights: finding the right balance for rifampicin-resistant TB treatment".
     Int J Tuberc Lung Dis. 2021;25:328-329.
     PubMed    
     
     
     
207. VAN DEUN A, Piubello A, Lynen L, de Jong BC, et al
     Human rights: finding the right balance for rifampicin-resistant TB treatment.
     Int J Tuberc Lung Dis. 2021;25:327-328.
     PubMed    
     
     
     
208. GULLON-BLANCO JA, Rodrigo-Sanz T, Alvarez-Navascues F, Tabernero-Huguet E, et al
     Completion of treatment for latent TB infection in a low prevalence setting.
     Int J Tuberc Lung Dis. 2021;25:321-323.
     PubMed    
     
     
     
209. ROY N, Krishnamoorthy Y, Rajaa S, Ezhumalai K, et al
     Health-related quality of life and its effect on TB treatment outcomes.
     Int J Tuberc Lung Dis. 2021;25:318-320.
     PubMed    
     
     
     
210. BHERING M, Duarte R, Kritski A
     Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil.
     Int J Tuberc Lung Dis. 2021;25:292-298.
     PubMed     Abstract available
     
     
     
211. CHESOV D, Butov D, Reimann M, Heyckendorf J, et al
     Impact of lung function on treatment outcome in patients with TB.
     Int J Tuberc Lung Dis. 2021;25:277-284.
     PubMed     Abstract available
     
     
     
212. VISCA D, D Ambrosio L, Centis R, Pontali E, et al
     Post-TB disease: a new topic for investigation-and why it matters.
     Int J Tuberc Lung Dis. 2021;25:258-261.
     PubMed    
     
     
     
213. LAU A, Ferrara G
     Disseminated TB: still being missed and misunderstood.
     Int J Tuberc Lung Dis. 2021;25:255-257.
     PubMed    
     
     
     
214. SCHULTINK MP, Kerstjens HAM, Ter Beek L, Zondag H, et al
     Assessment of TB treatment on patient well-being.
     Int J Tuberc Lung Dis. 2021;25:315-317.
     PubMed    
     
     
     March 2021
215. KUMAR MS, Surendran D, Manu MS, Rakesh PS, et al
     Mortality due to TB-COVID-19 coinfection in India.
     Int J Tuberc Lung Dis. 2021;25:250-251.
     PubMed    
     
     
     
216. GRACIAA DS, Kempker RR, Sanikidze E, Tukvadze S, et al
     TB research amidst the COVID-19 pandemic.
     Int J Tuberc Lung Dis. 2021;25:167-170.
     PubMed    
     
     
     
217. ALLWOOD BW, van der Zalm MM, Mortimer K
     Reply to "Clinical care for patients with post TB lung disease".
     Int J Tuberc Lung Dis. 2021;25:253-254.
     PubMed    
     
     
     
218. GUNTHER G, Ithete S
     Clinical care for patients with post-TB lung disease.
     Int J Tuberc Lung Dis. 2021;25:252-253.
     PubMed    
     
     
     
219. PARK JH, Jung J, Kim JY, Hong MJ, et al
     Airborne precautions based on Xpert((R)) MTB/RIF results for patients with presumptive TB.
     Int J Tuberc Lung Dis. 2021;25:244-246.
     PubMed    
     
     
     
220. KIZNY GORDON A, Tong SYC, Martinez E, Crighton T, et al
     TB genomic surveillance and data sharing in recognising contamination events.
     Int J Tuberc Lung Dis. 2021;25:241-243.
     PubMed    
     
     
     
221. BAIK Y, Nalutaaya A, Kitonsa PJ, Dowdy DW, et al
     Infection status of contacts is not associated with severity of TB in the index case.
     Int J Tuberc Lung Dis. 2021;25:237-240.
     PubMed    
     
     
     
222. ADANKWAH E, Arthur RA, Minadzi D, Owusu DO, et al
     Immune response against TB and non-tuberculous mycobacterial pulmonary disease.
     Int J Tuberc Lung Dis. 2021;25:234-236.
     PubMed    
     
     
     
223. MALIK AA, Fuad J, Abbass W, Ikhlaque S, et al
     Preventive treatment of drug-resistant TB in a rural setting.
     Int J Tuberc Lung Dis. 2021;25:231-233.
     PubMed    
     
     
     
224. CATES L, Crudu V, Codreanu A, Ciobanu N, et al
     Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting.
     Int J Tuberc Lung Dis. 2021;25:228-230.
     PubMed    
     
     
     
225. COX SR, Gupte AN, Thomas B, Gaikwad S, et al
     Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men.
     Int J Tuberc Lung Dis. 2021;25:182-190.
     PubMed     Abstract available
     
     
     
226. SOHN H, Sweeney S, Mudzengi D, Creswell J, et al
     Determining the value of TB active case-finding: current evidence and methodological considerations.
     Int J Tuberc Lung Dis. 2021;25:171-181.
     PubMed     Abstract available
     
     
     February 2021
227. BARRETT J, Painter H, Rajgopal A, Keane D, et al
     Increase in disseminated TB during the COVID-19 pandemic.
     Int J Tuberc Lung Dis. 2021;25:160-166.
     PubMed    
     
     
     
228. ALLWOOD BW, van der Zalm MM, Mortimer K
     Reply to: Taking action to improve post-TB lung health.
     Int J Tuberc Lung Dis. 2021;25:163a-163.
     PubMed    
     
     
     
229. HARRIES AD, Dlodlo RA, Brigden G, Chakaya JM, et al
     Taking action to improve post-TB lung health.
     Int J Tuberc Lung Dis. 2021;25:161-162.
     PubMed    
     
     
     
230. MOLINA-MOYA B, Guglielmetti L, Bothamley G, van Leth F, et al
     Use and impact of molecular methods for detecting drug-resistant TB.
     Int J Tuberc Lung Dis. 2021;25:157-159.
     PubMed    
     
     
     
231. LAW WS, Chan CKA, Leung CC
     Management of latent TB infection in child household contacts aged under 5 years.
     Int J Tuberc Lung Dis. 2021;25:151-153.
     PubMed    
     
     
     
232. MEHTA SN, Murrill M, Suryavanshi N, Bhosale R, et al
     TB-related knowledge and stigma among pregnant women in low-resource settings.
     Int J Tuberc Lung Dis. 2021;25:148-150.
     PubMed    
     
     
     
233. ARSCOTT-MILLS T, Ejelonu A, Mokalane K, Machao G, et al
     One third of child TB cases were missing from the national TB register in Botswana.
     Int J Tuberc Lung Dis. 2021;25:142-144.
     PubMed    
     
     
     
234. DE VOS E, Scott L, Voss De Lima Y, Warren RM, et al
     Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.
     Int J Tuberc Lung Dis. 2021;25:134-141.
     PubMed     Abstract available
     
     
     
235. SOTGIU G, Rosales-Klintz S, Centis R, D'Ambrosio L, et al
     TB management in the European Union/European Economic Area: a multi-centre survey.
     Int J Tuberc Lung Dis. 2021;25:126-133.
     PubMed     Abstract available
     
     
     
236. FOX GJ, Johnston JC, Nguyen TA, Majumdar SS, et al
     Active case-finding in contacts of people with TB.
     Int J Tuberc Lung Dis. 2021;25:95-105.
     PubMed     Abstract available
     
     
     
237. LINH NN, Miller C, Marks GB
     Potential benefits of active case finding to reduce the burden of TB.
     Int J Tuberc Lung Dis. 2021;25:93-94.
     PubMed    
     
     
     January 2021
238. SHEN X, Sha W, Yang C, Pan Q, et al
     Continuity of TB services during the COVID-19 pandemic in China.
     Int J Tuberc Lung Dis. 2021;25:81-83.
     PubMed    
     
     
     
239. 
     TB and COVID-19 co-infection: rationale and aims of a global study.
     Int J Tuberc Lung Dis. 2021;25:78-80.
     PubMed    
     
     
     
240. MAUG AKJ, Hossain MA, Gumusboga M, Decroo T, et al
     Finding the right balance between efficacy and tolerability for TB treatment: the search continues.
     Int J Tuberc Lung Dis. 2021;25:84-86.
     PubMed    
     
     
     
241. PARIGI S, Venturini E, Galli L, Chiappini E, et al
     Xpert((R)) MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates.
     Int J Tuberc Lung Dis. 2021;25:75-77.
     PubMed    
     
     
     
242. SAKR CJ, Musharrafieh UM, Banna HS, Hoteit RA, et al
     Risks and benefits of QuantiFERON((R))-TB testing for LTBI screening of health workers.
     Int J Tuberc Lung Dis. 2021;25:72-74.
     PubMed    
     
     
     
243. GENDERINI FG, Dauby N, Delforge M, De Wit S, et al
     TB in the intensive care unit in a low-endemic country.
     Int J Tuberc Lung Dis. 2021;25:69-71.
     PubMed    
     
     
     
244. NABISERE R, Arinaitwe A, Muyise R, Asienzo J, et al
     Implementation of TB preventive therapy in Uganda: effect of an intervention on completion rates.
     Int J Tuberc Lung Dis. 2021;25:64-65.
     PubMed    
     
     
     
245. TUCKER A, Oyuku D, Nalugwa T, Nantale M, et al
     Costs along the TB diagnostic pathway in Uganda.
     Int J Tuberc Lung Dis. 2021;25:61-63.
     PubMed    
     
     
     
246. MAVE V, Kadam D, Gaikwad S, Kinikar A, et al
     Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomes.
     Int J Tuberc Lung Dis. 2021;25:52-60.
     PubMed     Abstract available
     
     
     
247. MESFIN AB, Araia ZZ, Beyene HN, Mebrahtu AH, et al
     First molecular-based anti-TB drug resistance survey in Eritrea.
     Int J Tuberc Lung Dis. 2021;25:43-51.
     PubMed     Abstract available
     
     
     
248. SENEADZA NAH, Antwi S, Yang H, Enimil A, et al
     Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children.
     Int J Tuberc Lung Dis. 2021;25:36-42.
     PubMed     Abstract available
     
     
     
249. WROHAN I, Redwood L, Ho J, Velen K, et al
     Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
     Int J Tuberc Lung Dis. 2021;25:23-30.
     PubMed     Abstract available
     
     
     
250. SOH AZ, Tan CTY, Mok E, Chee CBE, et al
     Adipokines and the risk of active TB: a nested case-control study.
     Int J Tuberc Lung Dis. 2021;25:31-35.
     PubMed     Abstract available
     
     
     December 2020
251. ZHANG H, Cao X, Wang D, Xin H, et al
     The acquisition of Mycobacterium tuberculosis infection in village doctors in China: a prospective study.
     Int J Tuberc Lung Dis. 2020;24:1241-1246.
     PubMed     Abstract available
     
     
     
252. FANG JL, Chao CM, Tang HJ
     The impact of COVID-19 on the diagnosis of TB in Taiwan.
     Int J Tuberc Lung Dis. 2020;24:1321-1322.
     PubMed    
     
     
     
253. SINGH J, Ehtesham NZ, Hasnain SE
     Two parallel pandemics: the challenges faced by countries with COVID-19 and TB.
     Int J Tuberc Lung Dis. 2020;24:1319-1320.
     PubMed    
     
     
     November 2020
254. FATIMA R, Yaqoob A
     In Reply: How TB and COVID-19 compare: an opportunity to integrate both control programmes.
     Int J Tuberc Lung Dis. 2020;24:1227-1228.
     PubMed    
     
     
     
255. DE SOUZA CDF, Coutinho HS, Costa MM, Magalhaes MAFM, et al
     Impact of COVID-19 on TB diagnosis in Northeastern Brazil.
     Int J Tuberc Lung Dis. 2020;24:1220-1222.
     PubMed    
     
     
     
256. ZHOU S, Van Staden Q, Toska E
     Resource reprioritisation amid competing health risks for TB and COVID-19.
     Int J Tuberc Lung Dis. 2020;24:1215-1216.
     PubMed    
     
     
     
257. KADOTA JL, Reza TF, Nalugwa T, Kityamuwesi A, et al
     Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic.
     Int J Tuberc Lung Dis. 2020;24:1212-1214.
     PubMed    
     
     
     
258. HAAS MK, Ignatius EH, Stout JE, Dooley KE, et al
     Finding the right balance between efficacy and tolerability for TB treatment.
     Int J Tuberc Lung Dis. 2020;24:1225b-1226.
     PubMed    
     
     
     
259. WANG EY, Ahluwalia IB, Mase SR
     Response to Correspondence: The impact of smoking on TB treatment outcomes includes recurrent TB.
     Int J Tuberc Lung Dis. 2020;24:1225a-1225.
     PubMed    
     
     
     
260. DHAMGAYE TM
     In reply: Latent TB treatment in pregnant women: a patient perspective.
     Int J Tuberc Lung Dis. 2020;24:1226-1227.
     PubMed    
     
     
     
261. CHIANG CY, Bam TS
     The impact of smoking on TB treatment outcomes includes recurrent TB.
     Int J Tuberc Lung Dis. 2020;24:1224-1225.
     PubMed    
     
     
     October 2020
262. KIM HW, Min J, Shin AY, Koo HK, et al
     Reasons why patients with tuberculosis in South Korea stop anti-TB treatment: a cross-sectional study.
     Int J Tuberc Lung Dis. 2020;24:1016-1023.
     PubMed     Abstract available
     
     
     
263. SHAHRIARIRAD R, Fallahi MJ
     TB and the COVID-19 pandemic: brothers in arms against lung health.
     Int J Tuberc Lung Dis. 2020;24:1126-1127.
     PubMed    
     
     
     
264. WU Z, Chen J, Xia Z, Pan Q, et al
     Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China.
     Int J Tuberc Lung Dis. 2020;24:1122-1124.
     PubMed    
     
     
     
265. MENEGUIM AC, Rebello L, Das M, Ravi S, et al
     Adapting TB services during the COVID-19 pandemic in Mumbai, India.
     Int J Tuberc Lung Dis. 2020;24:1119-1121.
     PubMed    
     
     
     
266. HELDAL E, Dlodlo RA
     Estimating subnational TB burden-why not strengthen and use routine recording and reporting?
     Int J Tuberc Lung Dis. 2020;24:1125-1127.
     PubMed    
     
     
     
267. AKKERMAN OW, Tiberi S
     The importance of knowing why TB patients stop anti-TB treatment.
     Int J Tuberc Lung Dis. 2020;24:989-990.
     PubMed    
     
     
     September 2020
268. YASSIN M, Grzemska M
     Response to 'The Green Light Committee could contribute to ending tuberculosis .
     Int J Tuberc Lung Dis. 2020;24:984.
     PubMed    
     
     
     
269. NGUYEN TBP, Nguyen TA, Luu BK, Le TTO, et al
     A comparison of digital chest radiography and Xpert((R)) MTB/RIF in active case finding for tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:934-940.
     PubMed     Abstract available
     
     
     
270. CHIANG CH, Lee GH, Chiang TH, Tang PU, et al
     Disseminated Mycobacterium avium complex infection as a differential diagnosis of tuberculosis in HIV patients.
     Int J Tuberc Lung Dis. 2020;24:922-927.
     PubMed     Abstract available
     
     
     
271. LOVEDAY M, Hlangu S, Furin J
     Breastfeeding in women living with tuberculosis.
     Int J Tuberc Lung Dis. 2020;24:880-891.
     PubMed     Abstract available
     
     
     
272. ADEWOLE OO
     Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria.
     Int J Tuberc Lung Dis. 2020;24:981-982.
     PubMed    
     
     
     
273. VAN DER WALT M, Keddy KH
     How COVID-19 can instruct TB research: ensuring the safety of researchers exposed to infectious disease.
     Int J Tuberc Lung Dis. 2020;24:978-980.
     PubMed    
     
     
     
274. WILSON FA, Miller TL, Stimpson JP
     COVID-19 and TB control in immigrant communities.
     Int J Tuberc Lung Dis. 2020;24:975-977.
     PubMed    
     
     
     
275. ECHEVERRIA G, Espinoza W, de Waard JH
     How TB and COVID-19 compare: an opportunity to integrate both control programmes.
     Int J Tuberc Lung Dis. 2020;24:971-974.
     PubMed    
     
     
     
276. MULDER C, Nkiligi E, Kondo Z, Scholten JN, et al
     What to look for when using SUBsET for subnational TB incidence estimates.
     Int J Tuberc Lung Dis. 2020;24:983-984.
     PubMed    
     
     
     
277. WANG J, Garcia-Basteiro AL
     Should vitamin D supplementation be used concomitantly with LTBI treatment?
     Int J Tuberc Lung Dis. 2020;24:875-876.
     PubMed    
     
     
     August 2020
278. CHIANG CY
     Green Light Committee and WHO recommendations.
     Int J Tuberc Lung Dis. 2020;24:873-874.
     PubMed    
     
     
     June 2020
279. HARRIES AD
     In Response to Reinout van Crevel et al.
     Int J Tuberc Lung Dis. 2020;24:634.
     PubMed    
     
     
     May 2020
280. FURIN J
     Can Green Light Committees help "end TB"?
     Int J Tuberc Lung Dis. 2020;24:540.
     PubMed    
     
     
     April 2020
281. BASHAM CA, Romanowski K, Johnston JC
     Cardiovascular disease: the forgotten cousin of post-TB health?
     Int J Tuberc Lung Dis. 2020;24:466-467.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: